Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition
Jason M. Uslaner, Spencer J. Tye, Donnie Eddins, et al.
Science Translational Medicine (2013) Vol. 5, Iss. 179
Closed Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Circadian rhythm as a therapeutic target
Wei Ruan, Xiaoyi Yuan, Holger K. Eltzschig
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 4, pp. 287-307
Open Access | Times Cited: 293
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
How to fix a broken clock
Analyne M. Schroeder, Christopher S. Colwell
Trends in Pharmacological Sciences (2013) Vol. 34, Iss. 11, pp. 605-619
Open Access | Times Cited: 183
The Neurobiology of Sleep and Wakefulness
Michael D. Schwartz, Thomas S. Kilduff
Psychiatric Clinics of North America (2015) Vol. 38, Iss. 4, pp. 615-644
Open Access | Times Cited: 172
Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models
Yoko Irukayama‐Tomobe, Yasuhiro Ogawa, Hiromu Tominaga, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 22, pp. 5731-5736
Open Access | Times Cited: 126
Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness
Tomas Hökfelt, Swapnali Barde, Qing Xu, et al.
Frontiers in Neural Circuits (2018) Vol. 12
Open Access | Times Cited: 124
The Hypocretin/Orexin System Mediates the Extinction of Fear Memories
África Flores, Victòria Valls-Comamala, Giulia Costa, et al.
Neuropsychopharmacology (2014) Vol. 39, Iss. 12, pp. 2732-2741
Open Access | Times Cited: 119
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 113
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
Anthony L. Gotter, Christopher J. Winrow, Joseph Brunner, et al.
BMC Neuroscience (2013) Vol. 14, Iss. 1
Open Access | Times Cited: 88
The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry
Quanhui Chen, Luı́s de Lecea, Zhian Hu, et al.
Medicinal Research Reviews (2014) Vol. 35, Iss. 1, pp. 152-197
Closed Access | Times Cited: 79
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases
David Vanda, Paweł Zajdel, Miroslav Soural
European Journal of Medicinal Chemistry (2019) Vol. 181, pp. 111569-111569
Closed Access | Times Cited: 75
Orexin and Alzheimer’s Disease
Claudio Liguori
Current topics in behavioral neurosciences (2016), pp. 305-322
Open Access | Times Cited: 63
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia
Anthony J. Roecker, Swati P. Mercer, John D. Schreier, et al.
ChemMedChem (2013) Vol. 9, Iss. 2, pp. 311-322
Closed Access | Times Cited: 62
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review
Hayder M. Al‐kuraishy, MayH Abdulhadi, NawarR Hussien, et al.
Brain Circulation (2020) Vol. 6, Iss. 2, pp. 70-70
Open Access | Times Cited: 44
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
The hypocretins and the reward function: what have we learned so far?
Benjamin Boutrel, Nadia Steiner, Olivier Halfon
Frontiers in Behavioral Neuroscience (2013) Vol. 7
Open Access | Times Cited: 47
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
Peter de Boer, Wayne C. Drevets, Hany Rofael, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 6, pp. 668-677
Closed Access | Times Cited: 45
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44
Differential sleep-promoting effects of dual orexin receptor antagonists and GABAAreceptor modulators
Anthony L. Gotter, Susan L. Garson, Joanne Stevens, et al.
BMC Neuroscience (2014) Vol. 15, Iss. 1
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top